Skip to main content

Table 5 Number of participants reporting adverse events by body system

From: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo

Body system category

Total

Placebo

NAC

CT

(N = 181)

n = 61

n = 59

n = 61

Behavioural

38% (68)

33% (20)

34% (20)

44% (27)

Gastrointestinal

56% (101)

41% (25)

69% (41)*

57% (35)

Musculoskeletal

13% (24)

13% (8)

19% (11)

8% (5)

Neurological

17% (31)

23% (14)

10% (6)

18% (11)

Respiratory

34% (61)

39% (24)

36% (21)

26% (16)

Other

34% (62)

46% (28)

34% (20)

23% (14)*

  1. Note: NAC, N-acetylcysteine; CT, combination nutraceutical treatment. * Significantly different from the placebo, all other comparisons ns